Acetazolamide added to an SGLT2 inhibitor in type 2 diabetes
Tests acetazolamide added to SGLT2 inhibitors in type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Adding Acetazolamide on Top of SGLT2 Inhibition in Persons With Type 2 Diabetes
Key facts
- Where
- Toronto, CanadaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes who already take an SGLT2 inhibitor. It tests three doses of acetazolamide added to that treatment.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Established type 2 diabetes. HbA1c 10.0% (86 mmol/mol) or lower. eGFR 45 ml/min/1.73m2 or higher. Blood pressure 160/90 or lower and 90/60 mmHg or higher. BMI 18.5-45.0 kg/m2.
- Earlier treatment
- Must be on a stable dose of the highest dose of a RAAS inhibitor they can tolerate for at least 30 days. Cannot have used a carbonic anhydrase inhibitor in the 30 days before screening.
- Biomarker or test result
- Serum potassium must not be below 3.5 mmol/L. Serum bicarbonate must not be below 22 mEq/L.
Main reasons for not taking part
- Type 1 diabetes
- Allergy to acetazolamide, dapagliflozin or related products
- Liver disease or severe glaucoma
- Heart attack-type event, stroke or mini-stroke in the last 30 days
- Pregnancy, breastfeeding or planning pregnancy during the study
Read by machine on 9 November 2026.
Where in Canada
- Toronto General HospitalToronto, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT07902726
- Record updated
- 29 October 2026
- Original description
The study aims to determine the acute efficacy and safety of three sequential doses of acetazolamide (62.5 mg, 125 mg, 250 mg) each for 2 weeks in 20 patients with T2D receiving background SGLT2i therapy.Read full original descriptionShow less
Adding Acetazolamide on Top of SGLT2 Inhibition in Persons With Type 2 Diabetes ('DIPPER') Pilot Study
The study aims to determine the acute efficacy and safety of three sequential doses of acetazolamide (62.5 mg, 125 mg, 250 mg) each for 2 weeks in 20 patients with T2D receiving background SGLT2i therapy.
Inclusion: Signed and dated written informed consent; Adult (≥18 years) at the time of consent; Established T2D diagnosis as per Diabetes Canada; HbA1c ≤10.0%; eGFR ≥45 ml/min/1.73m2; BP ≤160/90 and ≥90/60 mmHg; BMI 18.5-45.0 kg/m2; On stable dose of maximally tolerated RAASi for ≥30 days.
Exclusion: Use of carbonic anhydrase inhibitor in the 30 days prior to screening; Acute coronary syndrome, stroke or transient ischemic attack within 30 days prior to screening; Participation in another drug trial within 30 days of screening; Established diagnosis of type 1 diabetes as per Diabetes Canada; With known or suspected hypersensitivity or allergy to acetazolamide, dapagliflozin or related products; Untreated urinary or genital tract infection; Any other clinical condition that, based on Investigator's judgement, would jeopardize patient safety during trial participation or would affect the study outcome; Serum potassium <3.5 mmol/L; Serum bicarbonate <22 mEq/L; Liver disease (hepatic cirrhosis, alcohol/drug abuse ≥3 months, or serum AST, ALT, or total bilirubin >3X the upper limit of normal); Iodine intolerance; Severe glaucoma; Active pregnancy, breastfeeding or planning to become pregnant during study period; Patient not able to understand and comply with study requirements, based on Investigator's judgment.